The Food and Drug Administration (FDA approved Auvelity, a non-antipsychotic tablet medication, offering a new option for treating agitation in adults with Alzheimer’s dementia. This approval is significant given that existing antipsychotics carry serious risks such as stroke and increased mortality.
Auvelity, which was already approved for the treatment of major depressive disorder, has demonstrated in clinical trials its effectiveness in relieving symptoms of agitation in Alzheimer’s patients by affecting neurotransmitters such as glutamate and dopamine.
“We have needed a drug like this for decades, because the agitation associated with Alzheimer’s disease is one of the most difficult and discouraging symptoms we treat,” he told ABC Records data Dr. Richard Issacson, director of research at the Florida Institute for Neurodegenerative Diseases. “This new drug would be used because its tolerability profile is better,” he added.
Warnings and side effects
However, although Auvelity shows promise, the FDA warns of possible side effects, including an increase in suicidal thoughts and other adverse reactions such as dizziness and seizures.
Specialized monitoring is required when starting treatment. Auvelity was initially approved by the FDA in 2022, but for the treatment of major depressive disorder in adults.
Alzheimer’s in numbers
As of 2026, approximately 7.4 million Americans over age 65 have Alzheimer’s dementia, and this number is projected to increase to 13.8 million by 2060, according to the Alzheimer’s Association.
According to a study published by JAMA Neurologybetween 50% and 60% of people with Alzheimer’s experience symptoms of agitation at some point, one of the most common and bothersome symptoms for those suffering from Alzheimer’s dementia.
Repercussions of Alzheimer’s
Alzheimer’s disease is a progressive and irreversible brain disorder that profoundly impairs cognitive faculties, leading to complete functional dependence and a significant emotional impact for both the patient and those around them. As neural connections break down and brain atrophy occurs, the person gradually loses their ability to reason, communicate, and perform everyday activities.
Functional impairment and dependency
The progression of the disease is manifested by a gradual loss of autonomy that begins with complex tasks and culminates in the need for total assistance.
- Initial phases: The individual experiences difficulty planning trips, managing finances, administering medication, or keeping up with medical appointments.
- Advanced phases: The dependence is absolute; Constant help is required for basic self-care activities such as dressing, feeding, and maintaining proper hygiene.
- Physical impact: Widespread brain damage compromises motor and communication abilities, often requiring adaptations to the patient’s physical environment.
Psychological and behavioral impact
Changes in the brain alter mood and behavior, which often represents one of the biggest challenges for coexistence and daily care.
Future prospects
Dr. Issacson stresses the importance of offering not only pharmacological treatments, but also complementary approaches such as exercise and diet.
The growing population affected by dementia demands continued attention and more research in this area.
You may also be interested in:
· Researchers can achieve early detection of Alzheimer’s through voice
· Serious infections: a new risk of dementia
· With records of almost 28 million Americans, they reveal what could be the direct cause of Alzheimer’s
